Barclays Reiterates Buy Rating on Twist Bioscience
Barclays maintains a positive outlook on Twist Bioscience, setting a $95 price target, a 4.85% downside from the current price.
Key Points
- Barclays reiterated its buy rating on Twist Bioscience (TWST) with a price target of $95 on June 24, 2026.
- Barclays's $95 price target implies 4.85% downside from Twist Bioscience Corporation's ($TWST) current $99.84 share price.
- Shares of Twist Bioscience traded near $85 on Wednesday, with a market cap of $5.3 billion and a 52-week high of $89.71.
- Insiders at Twist Bioscience, including CEO Emily Leproust, sold shares in June, while analysts maintain a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays has reiterated its buy rating on Twist Bioscience Corporation (NasdaqGS:TWST), maintaining a price target of $95. The update came from analyst Luke Sergott on June 24, 2026. Twist Bioscience shares were trading around $85 on Wednesday.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Twist Bioscience Corporation Stock Down 29.4%
On Wednesday, shares of Twist Bioscience traded near $85. The company has a market capitalization of about $5.3 billion. Though not currently profitable, it has a forward P/E ratio of -111.6 and a beta of 2.214, indicating higher volatility compared to the market. Over the past year, the stock has seen a low of $23.30 and a high of $89.71. The 50-day moving average is $62.46, while the 200-day moving average stands at $43.19. Twist Bioscience has a current ratio of 2.696, a quick ratio of 2.036, and a debt-to-equity ratio of 24.36.
$TWST price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Twist Bioscience reported revenue of $409.5 million, with a growth rate of 19.3%. Despite this growth, the company is not yet profitable, with a net margin of -19.8% and a return on equity of -18.2%. The next earnings report is expected on August 3, 2026.
Insider Buying and Selling at Twist Bioscience Corporation
In recent insider activity, Paula Green, the SVP of Human Resources, sold shares twice on June 15, 2026, at prices of $0 and $81.66 per share. Additionally, she purchased shares at $23.33 on the same day. On June 8, 2026, CEO Emily Leproust and other insiders, including Dennis Cho, sold shares at $69.84.
Analysts Set New Price Targets
Barclays maintained its buy rating with a $95 target on June 24, 2026. Other analysts have also shown confidence in Twist Bioscience. On June 15, TD Cowen maintained a buy rating with an $89 target, and Canaccord Genuity initiated coverage with a buy rating and a $90 target. Piper Sandler also initiated a buy rating with an $85 target on June 11.
About Twist Bioscience
Twist Bioscience Corporation, based in South San Francisco, California, develops and sells synthetic DNA-based products. Founded in 2013, the company serves the healthcare, diagnostics, and research sectors. Led by CEO Dr. Emily Marine Leproust, Twist Bioscience provides synthetic genes, DNA libraries, and NGS tools, among other products, to support various applications in academic and industrial settings. The company employs 979 people.
Bottom Line
Barclays' reiteration of its buy rating for Twist Bioscience highlights continued confidence in the company's growth potential. Investors often track such analyst insights for guidance, though it's important to remember that these ratings reflect past performance and expectations. As Twist Bioscience continues to innovate in the synthetic DNA space, its financial metrics and market position will be closely watched.
Get Twist Bioscience Corporation alerts
New 13F filings, insider trades, and analyst moves on $TWST, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.